Abstract
The purpose of this study is to evaluate the ocular findings in patients with the primary antiphospholipid syndrome (APS). Patients and methods: Twenty-two patients (44 eyes) with primary APS (17 women, 5 men) were examined. All patients were younger than 50 years (median age; 37.5 years). In 18 patients, fundus flourescein angiography was performed in addition to the ophthalmologic examination. Results: Sixteen patients (72.7%) described visual symptoms. Anterior segment was normal in 19 patients (86.4%). Posterior segment abnormalities were observed in 15 patients (68.2%). Venous dilatation and tortuosity were the most common ocular findings. Retinal vascular occlusive disease was detected in 5 patients (22.7%). Flourescein angiography abnormalities were noted in 14 of the 18 patients (77.8%). The most common angiographic finding was pigment epithelial window defects. Conclusions: Our results indicate that posterior eye segment involvement is relatively common in the primary APS. It also seems that the screening for APS is important in young patients with retinal vascular occlusion, especially in those without conventional risk factors.
Similar content being viewed by others
References
Harris EN. Antiphospholipid antibodies. Br J Haematol 1990; 74: 1–9.
Levine SR, Crofts JW, Lesser GR, Floberg J, Welch KMA. Visual symptoms associated with the presence of a lupus anticoagulant. Ophthalmology 1988; 95: 686–692.
Snyers B, Lambert M, Hardy JP. Retinal and choroidal vasoocclusive disease in systemic lupus erythematosus associated with antiphospholipid antibodies. Retina 1990; 10: 255–260.
Castañón C, Amigo MC, Banales JL, Nava A, Reyes PA. Ocular vaso−occlusive disease in primary antiphospholipid syndrome. Ophthalmology 1995: 102: 256–262.
Jonas J, Kölble K, Völcker HE, Kalden JR. Central retinal artery occlusion in Sneddon’s disease associated with antiphospholipid antibodies. Am J Ophthalmol 1986; 102: 37–40.
Kleiner RC, Najarian LV, Schatten S, Jabs DA, Patz A, Kaplan HJ. Vaso−occlusive retinopathy associated with antiphospholipid antibodies (lupus anticoagulant retinopathy). Ophthalmology 1989; 96: 896–904.
Watts MT, Greaves M, Rennie IG, Clearkin LG. Antiphospholipid antibodies in the aetiology of ischemic optic neuropathy. Eye 1991; 5: 75–79.
Dori D, Gelfand YA, Brenner B, Miller B. Cilioretinal artery occlusion: an ocular complication of primary antiphospholipid syndrome. Retina 1997; 17: 555–557.
Harris N, Pierangeli S. The Anticardiolipin ELISA. Techniques in Diagnostic Pathology 1991; 2: 21–42.
Triplett DA, Brandt JT, Kaczor D, Schaeffer J. Laboratory diagnosis of lupus inhibitors: A comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol 1983; 79: 679–682.
Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1994; 332: 912–917.
Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517–522.
Dhôte R, Bachmeyer C, Horellou MH, Toulon P, Christoforov B. Central retinal vein thrombosis associated with resistance to activated protein C. Am J Ophthalmol 1995; 120: 388–389.
Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64–67.
Vine AK, Samama MM. The role of abnormalities in the anticoagulant and fibrinolytic systems in retinal vascular occlusions. Surv Ophthalmol 1993; 37: 283–292.
Ordi−Ros J, Perez−Peman P, Monasterio J. Clinical and therapeutic aspects associated to phospholipid binding antibodies (lupus anticoagulant and anticardiolipin antibodies). Haemostasis 1994; 24: 165–174.
McNeil HP, Chesterman CN, Krilis SA. Anticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipid binding characteristics. Br J Haematol 1989; 73: 506–513.
Espinoza LR, Hartmann RC. Significance of the lupus anticoagulant. Am J Hematol 1986; 22: 331–337.
Oosting JD, Derksen RH, Bobbink IW, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993; 81: 2618–2625.
Rand JH, Wu X−X, Andree HA, Ross JB, Rusinova F, Gascon−Lema MG, et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin−V biding to phospholipids: A “Lupus Procoagulant” phenomenon. Blood 1998; 92: 1652–1660.
Rand PH. Antiphospholipid antibody syndrome: new insights on thrombogenic mechanisms. Am J Med Sci 1998; 316: 142–151.
Boets EP, Chaar CG, Ronday K, Keunen JE, Breedveld FC. Chorioretinopathy in primary antiphospholipid syndrome: a case report. Retina 1998; 18: 382–385.
Wiechens B, Schröder JO, Pötzsch B, Rochels R. Primary antiphospholipid antibody syndrome and retinal occlusive vasculopathy. Am J Ophthalmol 1997; 123: 848–850.
Pulido JS, Ward LM, Fischman GA, Goodwin JA, Froelich CJ, Sanghvi JP. Antiphospholipid antibodies associated with retinal vascular disease. Retina 1987; 7: 215–218.
Asherson RA, Merry P, Acheson JF, Harris EN, Hughes CR. Antiphospholipid antibodies: a risk factor for occlusive ocular vascular disease in systemic lupus erythematosus and the the ‘primary’ antiphospholipid syndrome. Ann Rheum Dis 1989; 48: 358–361
Acheson JF, Gregson RMC, Merry P, Schulenburg WE. Vasoocclusive retinopathy in the primary antiphospholipid antibody syndrome. Eye 1991; 5: 48–55.
Asherson RA, Cervera R. The Antiphospholipid Syndrome: a syndrome in evaluation. Ann Rheum Dis 1992; 51: 147–150.
Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117: 997–1002.
Amigo MC, Garcia−Torres R, Robbes M, Bochicchio T, Reyes PA. Renal involvement in primary antiphospholipid syndrome. J Rheumatol 1992; 19: 1181–1185.
Glacet−Bernard A, Bayani N, Chretien P, Cochard C, Lelong F, Coscas G. Antiphospholipid antibodies in retinal vascular occlusions. Arch Ophthalmol 1994; 112: 790–795.
Coniglio M, Platania A, Di Nucci GD, Arcieri P, Modzrewska R, Mariani G. Antiphosholipid−protein antibodies are not an uncommon feature in retinal venous occlusions. Thromb Res 1996; 83: 183–188.
Brenner B, Vulfsons SL, Lanir N, Nahir M. Coexistence of familial antiphospholipid syndrome and factor V Leiden: Impact on thrombotic diathesis. Br J Haematol 1996; 94: 166–167.
Montaruli B, Borchiellini A, Tamponi C, Giorda L, Bessone P, van Mourik JA, et al. Factor V Arg506→Gln mutation in patients with antiphospholipid antibodies. Lupus 1996; 5: 303–306.
Picillo U, De Lucia D, Palatiello E, Scuotto A, Marcialis MR, Pezzella S, et al. Association of primary antiphospholipid syndrome with inherited activated protein C resistance. J Rheumatol 1998; 25: 1232–1234.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Demirci, F.Y.K., Küçükkaya, R., Akarçay, K. et al. Ocular involvement in primary antiphospholipid syndrome. Int Ophthalmol 22, 323–329 (1998). https://doi.org/10.1023/A:1006305705080
Issue Date:
DOI: https://doi.org/10.1023/A:1006305705080